ABEO
Price
$5.43
Change
+$0.07 (+1.31%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
274.85M
52 days until earnings call
CRIS
Price
$1.67
Change
+$0.03 (+1.83%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
20.5M
Interact to see
Advertisement

ABEO vs CRIS

Header iconABEO vs CRIS Comparison
Open Charts ABEO vs CRISBanner chart's image
Abeona Therapeutics
Price$5.43
Change+$0.07 (+1.31%)
Volume$21.74K
Capitalization274.85M
Curis
Price$1.67
Change+$0.03 (+1.83%)
Volume$2.47K
Capitalization20.5M
ABEO vs CRIS Comparison Chart in %
Loading...
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRIS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABEO vs. CRIS commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABEO is a Buy and CRIS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (ABEO: $5.36 vs. CRIS: $1.64)
Brand notoriety: ABEO and CRIS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABEO: 114% vs. CRIS: 125%
Market capitalization -- ABEO: $274.85M vs. CRIS: $20.5M
ABEO [@Biotechnology] is valued at $274.85M. CRIS’s [@Biotechnology] market capitalization is $20.5M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABEO’s FA Score shows that 1 FA rating(s) are green whileCRIS’s FA Score has 0 green FA rating(s).

  • ABEO’s FA Score: 1 green, 4 red.
  • CRIS’s FA Score: 0 green, 5 red.
According to our system of comparison, ABEO is a better buy in the long-term than CRIS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABEO’s TA Score shows that 4 TA indicator(s) are bullish while CRIS’s TA Score has 3 bullish TA indicator(s).

  • ABEO’s TA Score: 4 bullish, 6 bearish.
  • CRIS’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ABEO is a better buy in the short-term than CRIS.

Price Growth

ABEO (@Biotechnology) experienced а -4.96% price change this week, while CRIS (@Biotechnology) price change was -4.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +9.50%, and the average quarterly price growth was +52.01%.

Reported Earning Dates

ABEO is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABEO($275M) has a higher market cap than CRIS($20.5M). ABEO YTD gains are higher at: -3.770 vs. CRIS (-46.405). ABEO has higher annual earnings (EBITDA): 80M vs. CRIS (-36.02M). ABEO has more cash in the bank: 226M vs. CRIS (10.1M). CRIS has less debt than ABEO: CRIS (2.31M) vs ABEO (24.1M). CRIS has higher revenues than ABEO: CRIS (11.4M) vs ABEO (400K).
ABEOCRISABEO / CRIS
Capitalization275M20.5M1,341%
EBITDA80M-36.02M-222%
Gain YTD-3.770-46.4058%
P/E Ratio8.38N/A-
Revenue400K11.4M4%
Total Cash226M10.1M2,238%
Total Debt24.1M2.31M1,044%
FUNDAMENTALS RATINGS
ABEO vs CRIS: Fundamental Ratings
ABEO
CRIS
OUTLOOK RATING
1..100
5760
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
56
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
20100
PRICE GROWTH RATING
1..100
6465
P/E GROWTH RATING
1..100
78100
SEASONALITY SCORE
1..100
5065

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRIS's Valuation (56) in the Biotechnology industry is in the same range as ABEO (76) in the Pharmaceuticals Generic industry. This means that CRIS’s stock grew similarly to ABEO’s over the last 12 months.

CRIS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ABEO (100) in the Pharmaceuticals Generic industry. This means that CRIS’s stock grew similarly to ABEO’s over the last 12 months.

ABEO's SMR Rating (20) in the Pharmaceuticals Generic industry is significantly better than the same rating for CRIS (100) in the Biotechnology industry. This means that ABEO’s stock grew significantly faster than CRIS’s over the last 12 months.

ABEO's Price Growth Rating (64) in the Pharmaceuticals Generic industry is in the same range as CRIS (65) in the Biotechnology industry. This means that ABEO’s stock grew similarly to CRIS’s over the last 12 months.

ABEO's P/E Growth Rating (78) in the Pharmaceuticals Generic industry is in the same range as CRIS (100) in the Biotechnology industry. This means that ABEO’s stock grew similarly to CRIS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABEOCRIS
RSI
ODDS (%)
Bullish Trend 2 days ago
89%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 18 days ago
75%
Declines
ODDS (%)
Bearish Trend 10 days ago
87%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRIS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LCTC3.150.05
+1.61%
Lifeloc Technologies, Inc.
NOBH28.760.01
+0.03%
Nobility Homes, Inc.
LBLCF38.57-0.19
-0.50%
Loblaw Companies Limited
DRMTY2.31-0.10
-3.96%
DR MARTENS PLC
CNVVY11.91-0.66
-5.25%
ConvaTec Group plc

CRIS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRIS has been loosely correlated with ABEO. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CRIS jumps, then ABEO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRIS
1D Price
Change %
CRIS100%
-2.96%
ABEO - CRIS
37%
Loosely correlated
-3.42%
VTGN - CRIS
37%
Loosely correlated
-2.88%
CGON - CRIS
35%
Loosely correlated
-0.55%
ROIV - CRIS
35%
Loosely correlated
+1.77%
OBIO - CRIS
34%
Loosely correlated
+0.41%
More